{
    "nct_id": "NCT05919147",
    "official_title": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Neuroendocrine Effects of Pioglitazone in Patients with Cancer and Cachexia",
    "inclusion_criteria": "* Age â‰¥18 years\n* Documented histologic or cytologic diagnosis of non-small-cell lung cancer or gastrointestinal cancer that is locally advanced and inoperable or metastatic (e.g., spread to distant organs)\n* Cachexia defined by Fearon criteria\n* Insulin resistance syndrome, defined with the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)\n* Ability to provide written informed consent, willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Provide written approval by a qualified healthcare professional\n* Allow the collection and storage of biospecimens and data for future use\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior diagnosis of type 2 diabetes\n* Prior or current thiazolidinedione (TZD) therapy\n* Known hypersensitivity to TZD\n* New York Heart Association (NYHA) class I-IV heart failure\n* History of or actively treated bladder cancer\n* Current use of CYP2C inhibitor (e.g., gemfibrozil) or CYP2C inducer (e.g., rifampin)\n* Inadequate hepatic function\n* Currently pregnant, breastfeeding, or planning to become pregnant within the next 16 weeks\n* Contraindications to magnetic resonance imaging (e.g., implanted cardiac device, cochlear implant)\n* Any other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol",
    "miscellaneous_criteria": ""
}